How FHIR and OMOP can shorten drug development and research time

Details

As the pharmaceutical industry increasingly incorporates Real-World Data (RWD) for regulatory compliance and developing new therapies, ensuring international interoperability is crucial. FHIR (Fast Healthcare Interoperability Resources) and OMOP CDM (Observational Medical Outcomes Partnership Common Data Model) are key standards for healthcare information exchange and clinical research, respectively. FHIR is a global standard for healthcare data exchange, while OMOP is a common data model used in over 4,000 organizations for clinical studies. Regulatory bodies like the EMA now require RWE (Real-World Evidence) alongside traditional trials. However, transforming patient data from hospital EHRs into OMOP format is extremely time-consuming and costly. InterSystems addresses this by offering a platform that uses FHIR's strength to convert RWD into OMOP in real-time, significantly reducing complex data processing times. This allows pharmaceutical companies to automate the RWD flow without writing code, facilitating expansion across multiple markets and regions, thereby accelerating the research development cycle. The implementation of this technology not only achieves data integration but also strengthens collaboration between healthcare providers and pharma companies, advancing precision medicine research. Nevertheless, challenges remain, including adapting to unique hospital system data models, the cost of data transformation, and ensuring compliance with strict regulations like GDPR.